Pemphigus Clinical Trial
— SHS-PemphigusOfficial title:
Identification of Vulnerability Factors in the Course of Pemphigus Patients - SHS Pemphigus Clinical Trial
The bullous pemphigoid treatment is based on corticosteroids continued for several years. Pemphigus causes some patients a psychological impact and sometimes major vulnerability that can occur not only at diagnosis but also at later stages of disease progression. Our hypothesis is that these episodes of vulnerability may be under four kinds of factors that may be connected to the plurality of the history of these patients, and the resources they can mobilize throughout this experience, generating inequality in management and "work" around the disease.
Status | Recruiting |
Enrollment | 48 |
Est. completion date | November 2018 |
Est. primary completion date | May 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Patient major - Patients with pemphigus vulgaris, diagnosed on a combination of: 1. clinical signs and 2. histological image above basal epithelial detachment with intra acantholysis, 3. direct immunofluorescence showing deposition of Immunoglobulin G and / or C3 to the surface of keratinocytes - Join a social security scheme - patient has been informed and have signed consent to participate in the study Exclusion Criteria: - Person placed under judicial protection, - Patient without liberty by administrative or judicial decision, - Patient participating in another trial for the duration of monitoring. |
Country | Name | City | State |
---|---|---|---|
France | Hôpital Avicenne | Bobigny | |
France | CHU de Clermont-Ferrand Hôpital d'Estaing | Clermont-Ferrand | |
France | CH du Mans | le Mans | |
France | CHRU de Lille Hôpital Claude Huriez | Lille | |
France | Hôpital La Timone, Assistance publique hôpitaux de Marseille-Aix | Marseille | |
France | Hôpital Haut-Lévêque | Pessac | |
France | Centre hospitalier de Cornouaille | Quimper | |
France | Hôpital Robert Debré, chu de Reims | Reims | |
France | University Hospital of Rouen | Rouen |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Rouen |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | analysis of vulnerability factors | evaluation of : perception by the patient of misdiagnosis, perception of a possible difference in assessment of the severity of his illness between himself and healthcare professionals, patient behavior in relation to available information sources, and the influence of information gathered on the illness experience, Patient trajectory during the diagnostic phase using individual interview and questionnaire | 12 months | |
Secondary | analysis of vulnerability factors | evaluation of : perception by the patient of misdiagnosis, perception of a possible difference in assessment of the severity of his illness between himself and healthcare professionals, patient behavior in relation to available information sources, and the influence of information gathered on the illness experience, Patient trajectory during the diagnostic phase using individual interview and questionnaire | 6 months | |
Secondary | assessment of anxiety, uncertainty, fear, coping strategies | assessment of anxiety, uncertainty, fear, coping strategies using individual interview and questionnaire | 12 months | |
Secondary | assessment of anxiety, uncertainty, fear, coping strategies | assessment of anxiety, uncertainty, fear, coping strategies using individual interview and questionnaire | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05534776 -
Validation of 5-Point Investigator Global Assessments for Pemphigus
|
||
Terminated |
NCT00278642 -
Hematopoietic Stem Cell Support in Patients With Autoimmune Bullous Skin Disorders
|
Phase 1 | |
Not yet recruiting |
NCT05898308 -
Comparison of a Personalized Maintenance Therapy With the Standard Treatment in Pemphigus
|
Phase 4 | |
Terminated |
NCT01559155 -
Role of Proteasomes in a Dermatological Autoimmune Disease: Bullous Pemphigoid
|
||
Active, not recruiting |
NCT01974518 -
Comparative Study of Rituximab Versus Combination of Rituximab and Intravenous Cyclophosphamide in Severe Pemphigus
|
Phase 3 | |
Recruiting |
NCT05284929 -
Human Leukocyte Antigen Class II (DRB1 and DQB1) Alleles and Haplotypes Frequencies in Patients With Pemphigus Vulgaris Among the Russian Population
|
||
Recruiting |
NCT05954416 -
FARD (RaDiCo Cohort) (RaDiCo-FARD)
|
||
Completed |
NCT00283712 -
Use of Infliximab for the Treatment of Pemphigus Vulgaris
|
Phase 2 | |
Not yet recruiting |
NCT06285435 -
Coagulation Activation in Patients With Pemphigus
|
||
Not yet recruiting |
NCT06454357 -
A Clinical Study of B007 in the Treatment of Pemphigus.
|
Phase 2/Phase 3 | |
Completed |
NCT01299857 -
Long-term Clinical and Biological Evaluation of Patients With Severe Forms of Pemphigus Treated by Rituximab
|
Phase 3 | |
Completed |
NCT00960713 -
The RITAI Cohort: An Observational Study on Rituximab Off-label Use for Auto-immune Disorders
|
N/A | |
Completed |
NCT00213512 -
Effect of Anti CD20 in Pemphigus Desease
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT04400994 -
IVIG With Rituximab vs Rituximab as First Line Treatment of Pemphigus
|
Phase 2 | |
Terminated |
NCT03075904 -
A Safety and Dose-Finding Study of SYNT001 in Subjects With Pemphigus (Vulgaris or Foliaceus)
|
Phase 1/Phase 2 | |
Terminated |
NCT03762265 -
A Study of PRN1008 in Patients With Pemphigus
|
Phase 3 | |
Recruiting |
NCT02365675 -
Wound Dressings for Pemphigus and Pemphigoid
|
N/A | |
Recruiting |
NCT01338103 -
Treatment of Pemphigus Patients With Rituximab 1000mgX2 and Assessment of Immune Status Via Cylex
|
N/A | |
Active, not recruiting |
NCT00656656 -
Immunoadsorption, Dexamethasone Pulse Therapy and Rituximab for Pemphigus
|
Phase 2 | |
Completed |
NCT00127764 -
European Trial of Adjuvant Oral Glucocorticoid Pulse Therapy in Pemphigus
|
Phase 2/Phase 3 |